Zoekresultaten - Portaal voor medische datamodellen (MDM-portaal)

Zoekresultaten filteren
Datamodellen selecteren

Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

41 Zoekresultaten.

Visit 16 GIMEMA CML0408 NCT00769327 - Visit 16

- 20-09-21 - 1 Formulier, 11 Itemgroepen, 117 Data-elementen, 2 Talen

Itemgroepen: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram, Echocardiogram, Biopsie, Preservation of cellular samples, Cytogenetics, FISH (from bone marrow blood), Molecular Biology (peripheral blood), FISH (peripheral blood)

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 16 Form

Visit 13 GIMEMA CML0408 NCT00769327 - Visit 13

- 20-09-21 - 1 Formulier, 5 Itemgroepen, 56 Data-elementen, 2 Talen

Itemgroepen: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram, Molecular Biology (peripheral blood)

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 13 Form

Visit 5 GIMEMA CML0408 NCT00769327 - Visit 5

- 20-09-21 - 1 Formulier, 4 Itemgroepen, 44 Data-elementen, 2 Talen

Itemgroepen: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 5 Form

Visit 7 GIMEMA CML0408 NCT00769327 - Visit 7

- 20-09-21 - 1 Formulier, 13 Itemgroepen, 127 Data-elementen, 2 Talen

Itemgroepen: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram, Echocardiogram, Biopsie, Preservation of cellular samples, Cytogenetics, NILOTINIB, FISH (from bone marrow blood), IMATINIB, Molecular Biology (peripheral blood), FISH (peripheral blood)

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 7 Form

Visit 3 GIMEMA CML0408 NCT00769327 - Visit 3

- 20-09-21 - 1 Formulier, 5 Itemgroepen, 49 Data-elementen, 2 Talen

Itemgroepen: Physical Examination, Complete Blood Count, NILOTINIB, Biochemistry, Electrocardiogram

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 3 Form

Visit 0 GIMEMA CML0408 NCT00769327 - Visit 0

- 20-09-21 - 1 Formulier, 4 Itemgroepen, 55 Data-elementen, 2 Talen

Itemgroepen: Enrollment, Symptoms, Physical Examination, Complete Blood Count

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 0 form.

Visit 8 GIMEMA CML0408 NCT00769327 - Visit 8

- 29-11-17 - 1 Formulier, 3 Itemgroepen, 28 Data-elementen, 2 Talen

Itemgroepen: Physical Examination, IMATINIB, Complete Blood Count

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 8 form.

Visit 14 GIMEMA CML0408 NCT00769327 - Visit 14

- 29-11-17 - 1 Formulier, 2 Itemgroepen, 23 Data-elementen, 2 Talen

Itemgroepen: Physical Examination, Complete Blood Count

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 14 form.

Visit 15 GIMEMA CML0408 NCT00769327 - Visit 15

- 29-11-17 - 1 Formulier, 2 Itemgroepen, 23 Data-elementen, 2 Talen

Itemgroepen: Physical Examination, Complete Blood Count

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 15 form.

Visit 12 GIMEMA CML0408 NCT00769327 - Visit 12

- 29-11-17 - 1 Formulier, 2 Itemgroepen, 23 Data-elementen, 2 Talen

Itemgroepen: Physical Examination, Complete Blood Count

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 12 form.

Visit 11 GIMEMA CML0408 NCT00769327 - Visit 11

- 29-11-17 - 1 Formulier, 2 Itemgroepen, 23 Data-elementen, 2 Talen

Itemgroepen: Physical Examination, Complete Blood Count

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 11 form.

Visit 9 GIMEMA CML0408 NCT00769327 - Visit 9

- 29-11-17 - 1 Formulier, 2 Itemgroepen, 23 Data-elementen, 2 Talen

Itemgroepen: Physical Examination, Complete Blood Count

RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 9 form.

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.